Nabriva Therapeutics has announced the appointment of Jennifer Schranz, M.D., as chief medical officer.

“Jennifer has broad expertise in infectious diseases and internal medicine with extensive experience in both clinical development and medical affairs for small molecules and biologics,” said Dr. Colin Broom, chief executive officer of Nabriva Therapeutics. “She brings a track record of successfully navigating the regulatory submission and approval process, as well as leading medical affairs activities and will be an invaluable member of our team as we continue to advance the lefamulin program toward a potential approval for the treatment of community-acquired bacterial pneumonia.”

Dr. Schranz joins Nabriva Therapeutics from Shire plc, with nearly two decades of experience in clinical development and medical affairs. She has extensive expertise working with small molecules, biologics, and vaccines in both small and large pharmaceutical companies. S

“Antimicrobial resistance to existing treatments is of critical public health importance,” said Dr. Schranz.  “This is a time of significant opportunity and a potential inflection point for Nabriva and I look forward to partnering with its experienced management team to advance the first truly new class of anti-infectives for intravenous and oral use in humans in nearly 20 years.”

Dr. Schranz held positions of increasing responsibility at Shire plc and at ViroPharma, most recently serving as the rare disease global development team lead where she oversaw clinical development, regulatory and life cycle management activities for the company’s hereditary angioedema franchise.